Schedule change proposed for ED drug


elderly man older man taking pill medicine medication viagra ED drug sildenafil

New proposal put forward for Pharmacist-Only sildenafil category

The TGA’s Advisory Committee on Medicines Scheduling is set to again review the possibility of creating an S3 category for sildenafil (Viagra).

There have been two previous requests for the drug to be down-scheduled in Australia. It has been available over the counter in New Zealand since 2014 and in the UK it is set to be available OTC later this year. 

The latest request called for the creation of a new Schedule 3 entry for sildenafil in oral preparations containing 50 mg of sildenafil per dosage unit in packs containing not more than 8 dosage units.

It also requested the drug be included in Appendix H to permit advertising; and to “include sildenafil in Appendix M to provide additional controls or supply requirements to allow sildenafil to be supplied by a pharmacist”.

Supply of Schedule 3 sildenafil would be contingent on the sponsor making CPD-accredited training available to pharmacists and providing a patient assessment tool to facilitate screening and counselling by the pharmacist.

The new proposal claims the move will increase access to sildenafil for men suffering from erectile dysfunction and will help de-stigmatise the condition.

It also claims the risks with non-prescription sildenafil are similar to those with the prescription product and can be “effectively managed in the pharmacy setting”.

It is set to be considered at the June 2018 meeting of the ACMS, alongside a number of other high-profile scheduling changes.

The full list of reasons provided by the proposals sponsor are:

  • Non-prescription availability of sildenafil 50 mg with appropriate informative consumer and pharmacist educational programmes, and advertising of Schedule 3 sildenafil 50 mg, will help to reach many men with erectile dysfunction (ED) who currently do not seek help from their doctor about their condition. It will also direct men away from the unregulated supply of purported ED medications.
  • The proposed re-scheduling will help destigmatise ED, raise awareness of the causes of ED and its association with more chronic conditions such as cardiovascular disease (CVD) and diabetes, encourage treatment seeking behaviour, and will offer the potential for earlier and more frequent interaction with the primary healthcare system.
  • The important risks for non-prescription sildenafil 50 mg are consistent with those that have been established for sildenafil in the prescription setting. These risks can be effectively managed in the pharmacy setting through routine risk minimisation measures that have been specifically tailored for non-prescription use. Benefits outweigh the risks, and all risks can be appropriately managed through Schedule 3 availability. Any incremental risks associated with non-prescription availability and advertising of sildenafil 50 mg can be effectively managed in the pharmacy setting through key measures such as pharmacist intervention at the point of sale, pharmacist training and consumer education.

Previous ‘The flu season is well and truly upon us.’
Next More codeine to be upscheduled?

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

5 Comments

  1. United we stand
    16/04/2018

    How the hell is a pharmacist meant to establish the cause of erectile dysfunction without a thorough medical history and physical examination to diagnose erectile dysfunction, and determine potential underlying causes.

    To top it off, there will be an expectation from both the pharmacy owner and the patient to establish adequacy of supply within 2-3 minutes. Let’s not forget the number of highly sensitive questions that needs to be asked at the counter, while the patient is surrounded by dozens of other people listening in.

    Keep it prescription only for godsakes. Otherwise every kid onthe block will expect to get some. Viagra will become dolased2.0

    • fiquet
      17/04/2018

      While I personally support the expansion of S3 , I 100% agree with you that ED drugs should stay on prescription for all the above reasons, unless pharmacies en masse install privacy booths for confidential discussion of S3/S4 items and other sensitive information.
      It seems for now wiser and safer for patients to keep ED drugs S4.

    • Jarrod McMaugh
      17/04/2018

      I had the impression that you were all about evidence.

      Care to point out where the issues you raise here have occurred in jurisdictions where PDE-5 inhibitors are able to be purchased without a prescription?

      • pagophilus
        18/04/2018

        I’ve come to realize through experience and meeting people that the way pharmacy is practiced in other jurisdictions is VERY different to the way we do things here.

    • PharmOwner
      17/04/2018

      We seem to cope quite well with managing privacy and sensitivity when fielding requests for the morning after pill. My issue is: if a gentleman has ED, what are the other medical issues behind it that require managing/diagnosing? I think GP land is still the most appropriate place for initiating ED therapy.

Leave a reply